Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Race Oncology Ltd has successfully and safely dosed the first patient in its Phase 1 clinical trial of RC220 for advanced solid tumours at the Southside Cancer Care Centre in Australia. This milestone marks the beginning of a program to assess the safety, tolerability, and therapeutic potential of RC220, with plans to recruit up to 32 more patients across Australia, Hong Kong, and South Korea. The trial aims to determine the maximum tolerated dose of RC220 in combination with doxorubicin and will use a Bayesian design for greater flexibility and speed. The outcome of this trial could impact Race Oncology’s positioning in the cancer treatment market and provide new options for patients with advanced solid tumours.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, bisantrene, is an anticancer drug known for its therapeutic benefits and reduced cardiotoxicity compared to anthracyclines like doxorubicin. The company is advancing a reformulated version, RC220, to meet unmet needs in oncology, particularly in anthracycline combinations.
YTD Price Performance: -25.93%
Average Trading Volume: 111,032
Technical Sentiment Signal: Buy
Current Market Cap: A$173.7M
For an in-depth examination of RAC stock, go to TipRanks’ Stock Analysis page.